A Multicountry, Multicentre, Non-interventional, Retrospective Study to determine Real-world treatment patterns and associated outcomes after First Line Osimertinib in patients with advanced and Metastatic NSCLC EGFRm in the GCC Region - TREASURE

Inclusion Criteria

• For inclusion in the study, all the following inclusion criteria must be fulfilled:
• 1. Patients with Stage IIIB–IV NSCLC using either AJCC 7th or 8th edition with EGFR
• mutation.
• 2. Age 18 or older at index date (specific age may vary according to country-specific
• guidelines)
• 3. Treated in the first line with Osimertinib from (April 1st, 2018, until December 31st,
• 2021).
• 4. Medical records available at the participating site reflect at least 9 months of follow-up
• from the index date (unless the patient died within the first 9 months of diagnosis).
• Note: specific databases may have additional inclusion criteria which will be detailed in
• country-specific protocol adaptations and statistical analysis plans (SAPs).